Apigenin shows up in skin research in two separate places that get blurred together. One is photoaging and ultraviolet damage. The other is inflammatory skin disease: psoriasis, atopic dermatitis, the conditions where the immune system is driving the problem rather than the sun. This article is about the second one, and the single most important detail is a delivery question. Almost every promising result was produced by putting apigenin on skin, not by swallowing it.
Key Takeaways
- The strongest psoriasis result used topically applied apigenin in mice, reducing PASI score and downregulating the IL-23 to IL-17 to IL-22 axis.
- A 2025 study named apigenin the principal active compound of a traditional anti-psoriatic herbal preparation, but dosed the whole preparation in animals, not pure apigenin.
- In cultured human keratinocytes apigenin raised filaggrin and loricrin, the barrier proteins whose loss is central to eczema. That happened in a dish at 20 micromolar.
- A 2022 review searching three databases concluded plainly that no clinical study has evaluated apigenin as a supplement for any skin condition.
- An oral capsule is not the intervention any of this tested, and the concentrations used are far above what oral apigenin reaches in blood.
The Topical Psoriasis Study
The most directly relevant experiment appeared in Life Sci in 2023.[1] Researchers used 5 percent imiquimod cream to induce psoriasis-like skin inflammation in BALB/c mice, which is the standard model for human psoriatic plaques, then applied apigenin topically.
Apigenin significantly reduced both the Psoriasis Area and Severity Index and the CosCam score, and improved histopathology. At the molecular level it downregulated CCR6, IL-17A and NF-kB, and reduced expression and secretion of cytokines across the IL-23 to IL-17 to IL-22 axis.
That axis is worth pausing on, because it is not an incidental detail. It is the pathway that modern psoriasis biologics target. Drugs such as the IL-17 and IL-23 inhibitors were developed precisely because that cascade drives plaque formation. A topical flavonoid nudging the same axis in a mouse is a coherent finding rather than a vague antioxidant claim.
The same paper ran an acute dermal toxicity study following OECD guidelines and found topical apigenin safe in that test. For a compound being proposed as a skin treatment, that is the right test to have run.
The 2025 Study, and What It Actually Dosed
A 2025 paper in Phytomedicine is frequently summarized as showing apigenin treats psoriasis.[2] The real structure of the study is more specific and the difference matters.
The researchers were investigating Qing Xue Wan and its component Dijincao, a traditional preparation used for psoriasis. They treated imiquimod-induced psoriatic mice with the herbal preparations and saw reduced PASI score, skin thickness, spleen index, inflammatory infiltration and serum cytokines. Then they used UPLC-QTOF mass spectrometry alongside lipopolysaccharide-stimulated human keratinocytes to work out which constituent was responsible, and identified apigenin as the principal active compound.
The mechanism they traced is genuinely novel: apigenin reduced keratinocyte hyperproliferation by inhibiting the CDK2 and E2F2 cell cycle pathway, alongside effects on IL-17 signaling. Psoriatic keratinocytes divide too fast, so a cell cycle brake is mechanistically appropriate.
The caveat is straightforward. The animals received the herbal preparation. Apigenin was identified as the active constituent through chemical analysis and cell work, which is a reasonable inference, but it is an inference. This study is not a test of apigenin given on its own to an animal.
The Barrier Protein Finding, and Where It Happened
The result with the most relevance to eczema came from a 2020 study in International Journal of Molecular Sciences using HaCaT human keratinocytes.[3] At 20 micromolar, apigenin increased expression of filaggrin, loricrin, aquaporin-3, hyaluronic acid and hyaluronic acid synthases 1, 2 and 3.
Filaggrin is not a minor player in this literature. Loss-of-function mutations in the filaggrin gene are among the best established genetic risk factors for atopic dermatitis, because filaggrin is a structural component of the skin barrier. A compound that raises filaggrin expression is acting on the actual defect rather than only on downstream itching and redness.
The same study found apigenin promoted expression of the antimicrobial peptides human beta-defensin 1, 2 and 3 and cathelicidin LL-37, which form the skin chemical barrier. Separately, in RBL-2H3 basophil-type cells at 30 micromolar, it inhibited Lyn, Syk and phospholipase C gamma 1 signaling, the high-affinity IgE receptor, and IL-4, IL-5 and IL-13, which is the allergic arm.
Two honest qualifications belong with this. First, all of it is cell culture. Filaggrin rising in a dish is not the same as a barrier repairing on a person. Second, the study was framed explicitly around cosmetic ingredient development and two of the author affiliations are cosmetics and life science companies. The work looks competently done and the authors declared no conflict, but the framing of a paper is worth knowing when reading its conclusions.
The Sentence Most Summaries Omit
A 2022 comprehensive review in Phytochemistry searched PubMed, Scopus and Web of Science for every study on apigenin in dermatological conditions.[4] It found preclinical support across ultraviolet damage, vitiligo, dermatitis, wounds, skin aging and some skin cancers.
It also stated, without hedging, that no clinical study has evaluated apigenin as a natural supplement for skin conditions. The authors concluded apigenin may be a future candidate and that clinical studies are needed to confirm safety and efficacy in skin care products.
That is the entire human evidence base for this topic: none. A 2023 review reached a similar position on apigenin in skin inflammatory disease and cancer.[5] Any content presenting apigenin as a psoriasis or eczema treatment is describing mouse and cell work.
Why the Capsule Question Is Not Pedantic
Someone reading the studies above and reaching for an oral supplement has changed the intervention in two ways at once.
The route is different. Topical application places the compound directly on the affected tissue at a concentration the researcher controls. That is why the psoriasis and dermatology work uses creams and gels, and why the 2022 review discusses novel delivery systems for both oral and topical bioavailability as an open research problem.
The concentration is different by orders of magnitude. Human pharmacokinetic work found free apigenin poorly absorbed, with urinary metabolite recovery equivalent to roughly 0.5 percent of intake, and what does circulate present mainly as glucuronide and sulfate conjugates rather than free apigenin.[6] The 20 and 30 micromolar concentrations that produced the keratinocyte and basophil effects are not concentrations a 25 mg or 50 mg capsule produces in blood.
The Practical Position
Psoriasis and moderate to severe atopic dermatitis are conditions where undertreatment has real costs. Psoriasis carries associations with psoriatic arthritis and cardiovascular risk, and uncontrolled eczema carries infection risk and sleep disruption. Substituting a supplement for prescribed therapy during a mild period is a decision whose downside arrives later.
Two specific cautions belong in a conversation with a dermatologist. Apigenin inhibits several cytochrome P450 enzymes, and methotrexate, ciclosporin and several other systemic psoriasis drugs have narrow therapeutic windows with monitoring attached. And the modern biologics for psoriasis already act on the IL-17 and IL-23 axis, which is the axis the mouse study reported apigenin affecting. Nobody has studied what stacking those does.
For anyone drawn to the topical evidence specifically, the honest summary is that the research supports investigating a topical apigenin formulation, and no such product has been tested in a person. Apigenin is also not the same as chamomile cream, which contains many other constituents.
Bottom Line
The inflammatory skin disease evidence for apigenin is more mechanistically pointed than most of this literature. Topical apigenin reduced psoriasis severity in mice while downregulating the same IL-23 to IL-17 to IL-22 axis that psoriasis biologics target, a 2025 study identified a cell cycle mechanism through CDK2 and E2F2, and cultured keratinocytes raised filaggrin and loricrin in response. Against that: the strongest animal result was topical, the 2025 animal dosing was of a herbal preparation rather than pure apigenin, the barrier protein work was in a dish at concentrations oral dosing does not reach, and a review searching three databases confirmed that no human being with a skin condition has been studied taking it.
Frequently Asked Questions
Does apigenin help psoriasis?
In mice with imiquimod-induced psoriasis, topically applied apigenin reduced the Psoriasis Area and Severity Index and downregulated CCR6, IL-17A, NF-kB and the IL-23 to IL-17 to IL-22 cytokine axis. A 2025 study additionally identified a CDK2 and E2F2 cell cycle mechanism. No human trial of apigenin in psoriasis has been conducted.
Should apigenin for skin be taken orally or applied topically?
The psoriasis and dermatology evidence was generated with topical application, not oral capsules. Human pharmacokinetic work shows free apigenin is poorly absorbed, with urinary recovery equivalent to roughly 0.5 percent of intake, so oral dosing does not reach the 20 to 30 micromolar concentrations used in the skin cell studies. No topical apigenin product has been tested in a person either.
Does apigenin help eczema or atopic dermatitis?
In cultured human keratinocytes apigenin at 20 micromolar increased filaggrin, loricrin, aquaporin-3 and hyaluronic acid synthases, plus antimicrobial peptides. Filaggrin loss is a well established genetic risk factor for atopic dermatitis, which makes the finding mechanistically relevant, but it occurred in cell culture. A 2022 review searching three databases found no clinical study of apigenin for any skin condition.
References
- Singh VK, Sahoo D, Agrahari K, et al. Anti-inflammatory, anti-proliferative and anti-psoriatic potential of apigenin in RAW 264.7 cells, HaCaT cells and psoriasis like dermatitis in BALB/c mice. Life Sciences (2023). PMID 37414141
- Alimujiang A, Kang Y, Wei W, et al. Apigenin suppresses keratinocyte hyperproliferation and inflammation in psoriasis by inhibiting CDK2/E2F2 pathway. Phytomedicine (2025). PMID 40516287
- Park CH, Min SY, Yu HW, et al. Effects of apigenin on RBL-2H3, RAW264.7, and HaCaT cells: anti-allergic, anti-inflammatory, and skin-protective activities. International Journal of Molecular Sciences (2020). PMID 32610574
- Majma Sanaye P, Mojaveri MR, Ahmadian R, et al. Apigenin and its dermatological applications: a comprehensive review. Phytochemistry (2022). PMID 35998830
- Yoon JH, Kim MY, Cho JY. Apigenin: a therapeutic agent for treatment of skin inflammatory diseases and cancer. International Journal of Molecular Sciences (2023). PMID 36675015
- Borges G, Fong RY, Ensunsa JL, et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radical Biology and Medicine (2022). PMID 35452808
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
